Back to top
more

Rigel Pharmaceuticals (RIGL)

(Real Time Quote from BATS)

$15.03 USD

15.03
124,482

+0.53 (3.66%)

Updated Nov 6, 2024 03:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Brokerage Reports

Research for RIGL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Rigel Pharmaceuticals, Inc. [RIGL]

Reports for Purchase

Showing records 1 - 20 ( 119 total )

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1

09/05/2024

Company Report

Pages: 4

MD Anderson Collaboration Off to a Good Start;Rezlidhia Triplet Combination Study Enrolls First Patient

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 2

09/03/2024

Daily Note

Pages: 3

Rigel and Kissei Deepen Ties; Rezlidhia Set for Asian Market Push

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 3

08/07/2024

Company Report

Pages: 8

2Q24 Results; Tavalisse Core Revenue as Rezlidhia and Gavreto Hitting Early Strides; Target Up to $57

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 4

06/25/2024

Company Report

Pages: 6

GAVRETO Set for Imminent U.S. Commercial Launch as Rigel Completes NDA Transfer

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 5

06/17/2024

Company Report

Pages: 11

Olutasidenib''s Position Continues to Strengthen with Multiple Presentations at EHA ''24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 6

06/03/2024

Company Report

Pages: 7

Olutasidenib''s Profile Building Continues With a Duo of Presentations at ASCO ''24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 7

05/08/2024

Company Report

Pages: 7

1Q24 Results; First Look at Phase 1b R289 Data by YE24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 8

03/06/2024

Company Report

Pages: 8

2023 Results; Heme-Onc Asset Revenues Continue to Climb; Commercialization Plan Laid Out For GAVRETO

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 9

02/22/2024

Company Report

Pages: 6

GAVRETO Joins Rigel''s Roster of Marketed Drugs Following Asset Acquisition

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 10

01/09/2024

Company Report

Pages: 9

Continued Pipeline Progress and Commercial Revenue Growth Signal Optimistic Outlook for 2024; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 11

01/04/2024

Daily Note

Pages: 8

Rigel CONNECTs Forces Through New Collaboration in Glioma

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 12

12/12/2023

Company Report

Pages: 9

Flurry of Encouraging Presentations Across Rezlidhia and Tavalisse at ASH; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 13

12/08/2023

Daily Note

Pages: 5

Rigel and MD Anderson Team Up to Broaden REZLIDHIA''s Reach Across Hematologic Cancers

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 14

11/08/2023

Company Report

Pages: 7

3Q23 Results; Shares Trading at 1x Projected 2024 Price to Sales Early in Commercial Phases; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 15

10/11/2023

Company Report

Pages: 6

COVID-19 Program Updates As Clinical Development Priority Moving Forward Remains On Heme-Onc

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 16

08/02/2023

Company Report

Pages: 6

2Q23 Results; Tavalisse Captures New Patients in Earlier Lines of Therapy; Rezlidhia New Traction Continues

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 17

05/03/2023

Company Report

Pages: 6

1Q23 Results; Tavalisse Continues to Ride the Revenue Wave; Rezlidhia Sales Gain Traction

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 18

03/08/2023

Company Report

Pages: 6

2022 Results; Tavalisse Blocking and Tackling; Rezlidhia Impresses Out of the Gate; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 19

01/09/2023

Company Report

Pages: 6

Tavalisse Beats; Rezlidhia Sales Up and Running; Time For New Clinical Developments

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 20

12/22/2022

Company Report

Pages: 6

Rezlidhia Launches in the U.S. With Confirmed Pricing Strategy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party
// eof